{"pmid":32487681,"title":"SARS-CoV-2 serology: Test, test, test, but interpret with caution!","text":["SARS-CoV-2 serology: Test, test, test, but interpret with caution!","SARS-CoV-2 serological tests are a subject of intense interest and have the potential to significantly enhance the diagnostic capability of healthcare services in the current pandemic. However, as with all novel assays, significant validation is required to understand the clinical relevance of results.We present the first study to assess clinician interpretation of SARS-CoV-2 serology scenarios. We identify common key assumptions regarding patient infectivity and protection that are not currently supported by the SARS-CoV-2 evidence base. In this rapidly developing field, we therefore strongly recommend serological assay results are accompanied by clear interpretive support from laboratory and infectious diseases specialists.","Clin Med (Lond)","Bermingham, William H","Wilding, Thomas","Beck, Sarah","Huissoon, Aarnoud","32487681"],"abstract":["SARS-CoV-2 serological tests are a subject of intense interest and have the potential to significantly enhance the diagnostic capability of healthcare services in the current pandemic. However, as with all novel assays, significant validation is required to understand the clinical relevance of results.We present the first study to assess clinician interpretation of SARS-CoV-2 serology scenarios. We identify common key assumptions regarding patient infectivity and protection that are not currently supported by the SARS-CoV-2 evidence base. In this rapidly developing field, we therefore strongly recommend serological assay results are accompanied by clear interpretive support from laboratory and infectious diseases specialists."],"journal":"Clin Med (Lond)","authors":["Bermingham, William H","Wilding, Thomas","Beck, Sarah","Huissoon, Aarnoud"],"date":"2020-06-04T11:00:00Z","year":2020,"_id":"32487681","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.7861/clinmed.2020-0170","keywords":["covid-19","sars-cov-2","interpretation of laboratory results","serology"],"topics":["Diagnosis"],"weight":1,"_version_":1668623433638871040,"score":9.490897,"similar":[{"pmid":32463475,"title":"[Rapid point-of-care serology testing for sars-cov-2].","text":["[Rapid point-of-care serology testing for sars-cov-2].","Increasing evidence indicates immunity against severe acute respiratory syndrome coronavirus 2 (sars-cov-2) after covid-19, but it remains unclear for how long the protection remains. Serology testing seems to have a higher sensitivity than molecular diagnostics from 8 days after onset of symtoms, and should be part of risk assessment and epidemiological studies of COVID-19. The performance of commercial serological point-of-care (POC) lateral flow tests are highly manufacturer-dependant. Low sensitivity increases the risk of false negative results and could result in unnecessary quarantine of test persons with developed antibodies. Low specificity increases the risk of false positive results and could lead to false assumptions of immunity. Carefully selected serological POC tests for sars-cov-2 can be used in large scale testing but should only be used by licensed medical staff able to understand their limitations and interpret the results.","Lakartidningen","Stackelberg, Otto","Esmaeilzadeh, Mouna","Olsen, Bjorn","Lundkvist, Ake","32463475"],"abstract":["Increasing evidence indicates immunity against severe acute respiratory syndrome coronavirus 2 (sars-cov-2) after covid-19, but it remains unclear for how long the protection remains. Serology testing seems to have a higher sensitivity than molecular diagnostics from 8 days after onset of symtoms, and should be part of risk assessment and epidemiological studies of COVID-19. The performance of commercial serological point-of-care (POC) lateral flow tests are highly manufacturer-dependant. Low sensitivity increases the risk of false negative results and could result in unnecessary quarantine of test persons with developed antibodies. Low specificity increases the risk of false positive results and could lead to false assumptions of immunity. Carefully selected serological POC tests for sars-cov-2 can be used in large scale testing but should only be used by licensed medical staff able to understand their limitations and interpret the results."],"journal":"Lakartidningen","authors":["Stackelberg, Otto","Esmaeilzadeh, Mouna","Olsen, Bjorn","Lundkvist, Ake"],"date":"2020-05-29T11:00:00Z","year":2020,"_id":"32463475","source":"PubMed","week":"202022|May 25 - May 31","topics":["Diagnosis"],"weight":1,"_version_":1668079521476116481,"score":205.37073},{"pmid":32397262,"title":"Nasopharyngeal and Oropharyngeal Swabs, And/Or Serology for SARS COVID-19: What Are We Looking For?","text":["Nasopharyngeal and Oropharyngeal Swabs, And/Or Serology for SARS COVID-19: What Are We Looking For?","Governments and clinicians that were fully involved in the dramatic SARS-CoV-2 outbreak during the last few weeks in Italy (and more or less all over the world) are fiercely debating the use of methods for screening this viral infection. Thus, all countries are employing a lot of resources in order to test more and more subjects. For this purpose, there are different strategies, based on either direct or indirect tests. Among the first category, the main assays used for SARS-CoV-2 are based on a real-time reverse transcriptase polymerase chain reaction (RT-PCR). Such tests can be performed on nasopharyngeal and oropharyngeal swabs for the categories of those with symptoms and those potentially exposed. In order to integrate the molecular assays in the diagnosis of SARS-CoV-2, a wide range of serology immunoassays (IAs) have also been developed. If we want to identify \"immune\" people in order to let them to come back to work, serology is the best (and probably the only) approach.","Int J Environ Res Public Health","Sanduzzi, Alessandro","Zamparelli, Stefano Sanduzzi","32397262"],"abstract":["Governments and clinicians that were fully involved in the dramatic SARS-CoV-2 outbreak during the last few weeks in Italy (and more or less all over the world) are fiercely debating the use of methods for screening this viral infection. Thus, all countries are employing a lot of resources in order to test more and more subjects. For this purpose, there are different strategies, based on either direct or indirect tests. Among the first category, the main assays used for SARS-CoV-2 are based on a real-time reverse transcriptase polymerase chain reaction (RT-PCR). Such tests can be performed on nasopharyngeal and oropharyngeal swabs for the categories of those with symptoms and those potentially exposed. In order to integrate the molecular assays in the diagnosis of SARS-CoV-2, a wide range of serology immunoassays (IAs) have also been developed. If we want to identify \"immune\" people in order to let them to come back to work, serology is the best (and probably the only) approach."],"journal":"Int J Environ Res Public Health","authors":["Sanduzzi, Alessandro","Zamparelli, Stefano Sanduzzi"],"date":"2020-05-14T11:00:00Z","year":2020,"_id":"32397262","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.3390/ijerph17093289","keywords":["covid-19","rt-pcr","sars","serology","swab"],"locations":["Italy","Oropharyngeal Swabs"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"topics":["Diagnosis"],"weight":1,"_version_":1666714494827495424,"score":190.73093},{"pmid":32350047,"title":"The Role of Antibody Testing for SARS-CoV-2: Is There One?","text":["The Role of Antibody Testing for SARS-CoV-2: Is There One?","The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) brought with it rapid development of both molecular and serologic assays for identification of COVID-19 infections. While Food and Drug Administration (FDA) emergency use authorization (EUA) is required for clinical application of SARS-CoV-2 molecular tests, submission for EUA is currently a voluntary process for manufacturers of serologic assays. The absence of FDA oversight of serologic tests is concerning, given that the commercially available serologic assays are highly variable, differing in their format, the antibody class detected, the targeted antigen and the acceptable specimen types. An added complication is the lack of a clear understanding for how such assays should be utilized and what the reported results ultimately indicate, or perhaps more importantly, what they do not indicate. Here, we provide a brief summary of the performance of a number of serologic assays reported in the literature, comment on what we do and do not know regarding our immune response to SARS-CoV-2, and provide a number of scenarios for which serologic testing will play a role in during our global response to this pandemic.","J Clin Microbiol","Theel, Elitza S","Slev, Patricia","Wheeler, Sarah","Couturier, Marc Roger","Wong, Susan J","Kadkhoda, Kamran","32350047"],"abstract":["The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) brought with it rapid development of both molecular and serologic assays for identification of COVID-19 infections. While Food and Drug Administration (FDA) emergency use authorization (EUA) is required for clinical application of SARS-CoV-2 molecular tests, submission for EUA is currently a voluntary process for manufacturers of serologic assays. The absence of FDA oversight of serologic tests is concerning, given that the commercially available serologic assays are highly variable, differing in their format, the antibody class detected, the targeted antigen and the acceptable specimen types. An added complication is the lack of a clear understanding for how such assays should be utilized and what the reported results ultimately indicate, or perhaps more importantly, what they do not indicate. Here, we provide a brief summary of the performance of a number of serologic assays reported in the literature, comment on what we do and do not know regarding our immune response to SARS-CoV-2, and provide a number of scenarios for which serologic testing will play a role in during our global response to this pandemic."],"journal":"J Clin Microbiol","authors":["Theel, Elitza S","Slev, Patricia","Wheeler, Sarah","Couturier, Marc Roger","Wong, Susan J","Kadkhoda, Kamran"],"date":"2020-05-01T11:00:00Z","year":2020,"_id":"32350047","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1128/JCM.00797-20","topics":["General Info"],"weight":1,"_version_":1666138495672909825,"score":187.92078},{"pmid":32459192,"title":"Molecular, serological, and biochemical diagnosis and monitoring of COVID-19: IFCC taskforce evaluation of the latest evidence.","text":["Molecular, serological, and biochemical diagnosis and monitoring of COVID-19: IFCC taskforce evaluation of the latest evidence.","The global coronavirus disease 2019 (COVID-19) has presented major challenges for clinical laboratories, from initial diagnosis to patient monitoring and treatment. Initial response to this pandemic involved the development, production, and distribution of diagnostic molecular assays at an unprecedented rate, leading to minimal validation requirements and concerns regarding their diagnostic accuracy in clinical settings. In addition to molecular testing, serological assays to detect antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are now becoming available from numerous diagnostic manufacturers. In both cases, the lack of peer-reviewed data and regulatory oversight, combined with general misconceptions regarding their appropriate use, have highlighted the importance of laboratory professionals in robustly validating and evaluating these assays for appropriate clinical use. The International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Task Force on COVID-19 has been established to synthesize up-to-date information on the epidemiology, pathogenesis, and laboratory diagnosis and monitoring of COVID-19, as well as to develop practical recommendations on the use of molecular, serological, and biochemical tests in disease diagnosis and management. This review summarizes the latest evidence and status of molecular, serological, and biochemical testing in COVID-19 and highlights some key considerations for clinical laboratories operating to support the global fight against this ongoing pandemic. Confidently this consolidated information provides a useful resource to laboratories and a reminder of the laboratory's critical role as the world battles this unprecedented crisis.","Clin Chem Lab Med","Bohn, Mary Kathryn","Lippi, Giuseppe","Horvath, Andrea","Sethi, Sunil","Koch, David","Ferrari, Maurizio","Wang, Cheng-Bin","Mancini, Nicasio","Steele, Shannon","Adeli, Khosrow","32459192"],"abstract":["The global coronavirus disease 2019 (COVID-19) has presented major challenges for clinical laboratories, from initial diagnosis to patient monitoring and treatment. Initial response to this pandemic involved the development, production, and distribution of diagnostic molecular assays at an unprecedented rate, leading to minimal validation requirements and concerns regarding their diagnostic accuracy in clinical settings. In addition to molecular testing, serological assays to detect antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are now becoming available from numerous diagnostic manufacturers. In both cases, the lack of peer-reviewed data and regulatory oversight, combined with general misconceptions regarding their appropriate use, have highlighted the importance of laboratory professionals in robustly validating and evaluating these assays for appropriate clinical use. The International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Task Force on COVID-19 has been established to synthesize up-to-date information on the epidemiology, pathogenesis, and laboratory diagnosis and monitoring of COVID-19, as well as to develop practical recommendations on the use of molecular, serological, and biochemical tests in disease diagnosis and management. This review summarizes the latest evidence and status of molecular, serological, and biochemical testing in COVID-19 and highlights some key considerations for clinical laboratories operating to support the global fight against this ongoing pandemic. Confidently this consolidated information provides a useful resource to laboratories and a reminder of the laboratory's critical role as the world battles this unprecedented crisis."],"journal":"Clin Chem Lab Med","authors":["Bohn, Mary Kathryn","Lippi, Giuseppe","Horvath, Andrea","Sethi, Sunil","Koch, David","Ferrari, Maurizio","Wang, Cheng-Bin","Mancini, Nicasio","Steele, Shannon","Adeli, Khosrow"],"date":"2020-05-28T11:00:00Z","year":2020,"_id":"32459192","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1515/cclm-2020-0722","keywords":["covid-19","sars-cov-2","biochemical monitoring","molecular testing","serology testing"],"topics":["Diagnosis"],"weight":1,"_version_":1667967698909265920,"score":175.49477},{"pmid":32402061,"title":"Clinical Performance of Two SARS-CoV-2 Serologic Assays.","text":["Clinical Performance of Two SARS-CoV-2 Serologic Assays.","BACKGROUND: The recent emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in a rapid proliferation of serologic assays. However, little is known about their clinical performance. Here, we compared two commercial SARS-CoV-2 IgG assays. METHODS: 103 specimens from 48 patients with PCR confirmed SARS-CoV-2 infections and 153 control specimens were analyzed using SARS-CoV-2 serologic assays by Abbott and EUROIMMUN (EI). Duration from symptom onset was determined by medical record review. Diagnostic sensitivity, specificity, and concordance were calculated. RESULTS: The Abbott SARS-CoV-2 assay had a diagnostic specificity of 99.4% (95% CI; 96.41-99.98%), and sensitivity of 0.0% (95% CI; 0.00-26.47%) at <3 days post symptom onset, 30.0% (95% CI; 11.89-54.28) at 3-7d, 47.8% (95% CI; 26.82-69.41) at 8-13d and 93.8% (95% CI; 82.80-98.69) at >/=14d. Diagnostic specificity on the EI assay was 94.8% (95% CI; 89.96-97.72) if borderline results were considered positive and 96.7% (95% CI; 92.54-98.93) if borderline results were considered negative. The diagnostic sensitivity was 0.0% (95% CI; 0.00-26.47%) at <3d, 25.0% (95% CI; 8.66-49.10) at 3-7d, 56.5% (95% CI; 34.49-76.81) at 3-7d and 85.4% (95% CI; 72.24-93.93) at >/=14d if borderline results were considered positive. The qualitative concordance between the assays was 0.83 (95% CI; 0.75-0.91). CONCLUSIONS: The Abbott SARS-CoV-2 assay had fewer false positive and false negative results than the EI assay. However, diagnostic sensitivity was poor in both assays during the first 14 days of symptoms.","Clin Chem","Tang, Mei San","Hock, Karl G","Logsdon, Nicole M","Hayes, Jennifer E","Gronowski, Ann M","Anderson, Neil W","Farnsworth, Christopher W","32402061"],"abstract":["BACKGROUND: The recent emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in a rapid proliferation of serologic assays. However, little is known about their clinical performance. Here, we compared two commercial SARS-CoV-2 IgG assays. METHODS: 103 specimens from 48 patients with PCR confirmed SARS-CoV-2 infections and 153 control specimens were analyzed using SARS-CoV-2 serologic assays by Abbott and EUROIMMUN (EI). Duration from symptom onset was determined by medical record review. Diagnostic sensitivity, specificity, and concordance were calculated. RESULTS: The Abbott SARS-CoV-2 assay had a diagnostic specificity of 99.4% (95% CI; 96.41-99.98%), and sensitivity of 0.0% (95% CI; 0.00-26.47%) at <3 days post symptom onset, 30.0% (95% CI; 11.89-54.28) at 3-7d, 47.8% (95% CI; 26.82-69.41) at 8-13d and 93.8% (95% CI; 82.80-98.69) at >/=14d. Diagnostic specificity on the EI assay was 94.8% (95% CI; 89.96-97.72) if borderline results were considered positive and 96.7% (95% CI; 92.54-98.93) if borderline results were considered negative. The diagnostic sensitivity was 0.0% (95% CI; 0.00-26.47%) at <3d, 25.0% (95% CI; 8.66-49.10) at 3-7d, 56.5% (95% CI; 34.49-76.81) at 3-7d and 85.4% (95% CI; 72.24-93.93) at >/=14d if borderline results were considered positive. The qualitative concordance between the assays was 0.83 (95% CI; 0.75-0.91). CONCLUSIONS: The Abbott SARS-CoV-2 assay had fewer false positive and false negative results than the EI assay. However, diagnostic sensitivity was poor in both assays during the first 14 days of symptoms."],"journal":"Clin Chem","authors":["Tang, Mei San","Hock, Karl G","Logsdon, Nicole M","Hayes, Jennifer E","Gronowski, Ann M","Anderson, Neil W","Farnsworth, Christopher W"],"date":"2020-05-14T11:00:00Z","year":2020,"_id":"32402061","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1093/clinchem/hvaa120","keywords":["covid-19","sars-cov-2","serology"],"locations":["Abbott"],"topics":["Diagnosis"],"weight":1,"_version_":1666714494963810304,"score":172.09224}]}